研究团队对7例TNBC患者(HER2-negative vs HER2-low,4 vs 3)的36168个细胞进行单细胞RNA测序(scRNA-seq),以进一步探索两种不同表型的TNBC之间肿瘤生物学特性的差异。结果显示: 与HER2-low TNBC相比,HER2-negativeative TNBC内皮细胞(1.8%对8...
抗HER2靶向治疗+化疗+内分泌治疗用于新发病例患者的比例相比复发性疾病患者的比例更高 [55.2%(175/317)vs 36.7%(135/368)]，接受曲妥珠单抗+帕妥珠单抗+紫杉类治疗方案的患者比例也是如此 [伴或不伴内分泌治疗；71.0
[6] Lu YS, Mahidin EIBM, Azim H, et al. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol...
[15]Oliveira M,et al Camizestrant,a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer:Results of the randomized,multi-dose Phase 2 SERENA-2 trial.2022 SABCS.GS3-02. *此文仅用于向医学人士提供科学信息,不代表本平台观点...
[24]Cantini L, Trapani D, Guidi L, Boscolo Bielo L, et al. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer. Cancer Treat Rev. 2024 Feb;123:102669. [25]Curigliano G, Castelo-Branco L...
导语：在乳腺癌研究领域，HER2低表达肿瘤的基因组特征及其与临床治疗的相关性一直缺乏清晰定义。Nature子刊最新发表的一篇研究填补了这一空白。研究团队通过对超过1000例转移性乳腺癌患者的基因组数据进行深入分析，揭示了HER2低表达与HER2阴性肿瘤之间的分子差异，为精准医疗提供了新的视角，并可能重塑乳腺癌的治疗策略。乳...
[2].Hurvitz SA,Hegg R,Chung WP,et al.Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer:updated results from DESTINY-Breast03,a randomised,open-label,phase 3 trial.Lancet 2023;401:105-17. ...
对于HER2 低表达的 TNBC 患者,NP-S 联合曲妥珠单抗及 GM-CSF 作为术后辅助治疗,3 年无病生存率显著提高(94.1% vs 66.9%,P = 0.01)。 HER2 低表达乳腺癌的治疗面临的挑战 HER2 低表达重塑乳腺癌的分子分型 近期,《Lancet Oncology》发表了一篇文章,文章对乳腺癌术前新辅助治疗 4 项前瞻临床试验中随机入组...
Sara M Tolaney et al. Lancet Oncol. 2023 Mar;24(3):273-285.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial 编辑|r.G 审核|贾巍教授...
[2]https://seer.cancer.gov/statfacts/html/breast-subtypes.html [3]Loibl S, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated...